

May 7, 2025

To Shareholders,

Company Name: Renascience Inc.  
Representative: Keisuke Furuta, President & CEO  
(Code: 4889 TSE Growth)  
For inquiries, please contact Administration Dept.

**Notice of confirmation of additional grant for Innovative Cancer Medical Practical Research  
Project by the Japan Agency for Medical Research and Development (AMED).**

Our company is currently conducting a Phase III clinical trial of the PAI-1 inhibitor RS5614 for chronic myeloid leukemia (CML). This clinical trial was selected for AMED's "the innovative Cancer Medical Practical Research Program" in fiscal year 2022 (representative institution: National University Corporation Tohoku University, our company is a contributing institution), and last year was the final year (implementation period: fiscal year 2022 to fiscal year 2024, total grant amount: 190 million yen). In the evaluation by AMED of the final year, an extension of the grant period of two years was approved (disclosed on December 3, 2024), because the registration of the target number of cases had been completed and it was expected that the trial would be completed within the two-year extension period. We would like to inform you that the grant amount of this year for the Phase III clinical trial has been confirmed.

■ Subsidy amount

FY ending March 2026: 52 million yen

This matter will be incorporated into the full-year financial forecast for the fiscal year ending March 2026, which is scheduled to be announced on May 14, 2025.